NBTXR-3 for treating advanced soft tissue sarcoma (terminated appraisal) (TA745)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 10 November 2021
Trabectedin for the treatment of advanced soft tissue sarcoma (TA185)Product type:GuidanceProgramme:Technology appraisal guidanceLast updated: 8 February 2021Published: 24 February 2010
Entrectinib for treating NTRK fusion-positive solid tumours (TA644)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 12 August 2020
Regorafenib for previously treated unresectable or metastatic gastrointestinal stromal tumours (TA488)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 15 November 2017
Imatinib for the adjuvant treatment of gastrointestinal stromal tumours (TA326)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 26 November 2014
Mifamurtide for the treatment of osteosarcoma (TA235)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 26 October 2011
Imatinib for the treatment of unresectable and/or metastatic gastrointestinal stromal tumours (TA209)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 24 November 2010
Imatinib for the treatment of unresectable and/or metastatic gastro-intestinal stromal tumours (TA86)Product type:GuidanceProgramme:Technology appraisal guidanceLast updated: 1 November 2010Published: 27 October 2004
Sunitinib for the treatment of gastrointestinal stromal tumours (TA179)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 23 September 2009
NY-ESO-1 T-cells for treating synovial sarcoma ID1286Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Selinexor for treating unresectable dedifferentiated advanced liposarcoma [ID3825]Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Afamitresgene autoleucel for previously treated MAGE-A4 positive advanced synovial sarcoma or myxoid round cell liposarcoma [ID4064]Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Letetresgene autoleucel for treating NY-ESO-1 advanced unresectable synovial sarcoma in people aged 10 and over or NY-ESO-1 advanced unresectable myxoid round cell liposarcoma in adults TS ID 10652Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
BI 907828 for untreated dedifferentiated advanced liposarcoma [ID6296]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC